MADISON, Wis.--(BUSINESS WIRE)--A new microsatellite instability (MSI) system launched today by Promega Corporation enables cancer researchers to evaluate a new set of unique MSI markers that may ...
The supplemental biologics license application (sBLA) for Keytruda (pembrolizumab) is still under review by the Food and Drug Administration (FDA) to treat MSI-H cancer. The supplemental biologics ...
Paris, March 12, 2025 – MSInsight, an innovative start-up specializing in precision medicine in oncology, announces the successful completion of its €1.6 million seed funding round. This fundraising ...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
Bottom Line: Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly ...
Bottom Line: Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly ...
NOUS-209 is being evaluated in multiple clinical studies targeting MSI cancers, from early-stage cancer interception through to metastatic disease BASEL, Switzerland – 19 th November 2024 - Nouscom, a ...
Dr. Nguyen will discuss the disparities in colorectal cancer outcomes and how precision medicine has the potential to exacerbate health disparities due to differences in access and implementation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback